Literature DB >> 21349363

Population diversity in batches of the varicella Oka vaccine.

R K Kanda1, M L Quinlivan, A A Gershon, R A Nichols, J Breuer.   

Abstract

The Oka vaccine is a live attenuated vaccine for the prevention of varicella. Although the vaccine differs from the progenitor virus by over 40 mutations, only three of these are fixed, the rest being a mixture of the wildtype and the vaccine allele. To examine the extent of this variability between two of the three commercially available vaccine preparations, we analysed the vaccine/wildtype allele frequencies present at fifteen vaccine loci in five preparations each from two different manufacturers of the vOka vaccine. Our results suggest that differences in manufacturing processes between the two companies have resulted in significant variation in the frequencies of the vaccine/wildtype alleles in their vaccines. Yet despite these differences, the allele frequencies in the vaccines from the two companies are strongly correlated. We discuss the significance of these findings and the role of evolutionary processes that influence the production of this live attenuated vaccine.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21349363      PMCID: PMC5381798          DOI: 10.1016/j.vaccine.2011.02.021

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  18 in total

1.  A comparison of safety, tolerability and immunogenicity of Oka/Merck varicella vaccine and VARILRIX in healthy children.

Authors:  Yu-Lung Lau; S J Rupert Vessey; Ivan S F Chan; Tsz-Leung Lee; Li-Min Huang; Chin-Yun Lee; Tzou-Yien Lin; Bee Wah Lee; Kow Kwan; Siti M Kasim; Christina Y Chan; Karen M Kaplan; Daniel J Distefano; Anna L Harmon; Amy Golie; Jonathan Hartzel; Jin Xu; Shu Li; Holly Matthews; Jerald C Sadoff; Alan Shaw
Journal:  Vaccine       Date:  2002-07-26       Impact factor: 3.641

2.  Rashes occurring after immunization with a mixture of viruses in the Oka vaccine are derived from single clones of virus.

Authors:  Mark L Quinlivan; Anne A Gershon; Sharon P Steinberg; Judith Breuer
Journal:  J Infect Dis       Date:  2004-07-15       Impact factor: 5.226

Review 3.  Molecular studies of Varicella zoster virus.

Authors:  Mark Quinlivan; Judith Breuer
Journal:  Rev Med Virol       Date:  2006 Jul-Aug       Impact factor: 6.989

4.  Analysis of varicella zoster virus attenuation by evaluation of chimeric parent Oka/vaccine Oka recombinant viruses in skin xenografts in the SCIDhu mouse model.

Authors:  Leigh Zerboni; Stewart Hinchliffe; Marvin H Sommer; Hideki Ito; Jaya Besser; Shaye Stamatis; Jason Cheng; Daniel Distefano; Nikolai Kraiouchkine; Alan Shaw; Ann M Arvin
Journal:  Virology       Date:  2005-02-05       Impact factor: 3.616

5.  Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.

Authors:  Mark L Quinlivan; Anne A Gershon; Mahmoud M Al Bassam; Sharon P Steinberg; Philip LaRussa; Richard A Nichols; Judith Breuer
Journal:  Proc Natl Acad Sci U S A       Date:  2006-12-20       Impact factor: 11.205

6.  Oka varicella vaccine is distinguishable from its parental virus in DNA sequence of open reading frame 62 and its transactivation activity.

Authors:  Y Gomi; T Imagawa; M Takahashi; K Yamanishi
Journal:  J Med Virol       Date:  2000-08       Impact factor: 2.327

7.  Safety profile of live varicella virus vaccine (Oka/Merck): five-year results of the European Varicella Zoster Virus Identification Program (EU VZVIP).

Authors:  Nicolas Goulleret; Elodie Mauvisseau; Mélanie Essevaz-Roulet; Mark Quinlivan; Judy Breuer
Journal:  Vaccine       Date:  2010-06-30       Impact factor: 3.641

8.  DNA sequence variability in isolates recovered from patients with postvaccination rash or herpes zoster caused by Oka varicella vaccine.

Authors:  Vladimir N Loparev; Elena Rubtcova; Jane F Seward; Myron J Levin; D Scott Schmid
Journal:  J Infect Dis       Date:  2007-01-10       Impact factor: 5.226

9.  Comparative varicella vaccine effectiveness during outbreaks in day-care centres.

Authors:  M Spackova; M Wiese-Posselt; M Dehnert; D Matysiak-Klose; U Heininger; A Siedler
Journal:  Vaccine       Date:  2009-10-27       Impact factor: 3.641

10.  Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination.

Authors:  Christian R Frey; Margaret A Sharp; Andrew S Min; D Scott Schmid; Vladimir Loparev; Ann M Arvin
Journal:  J Infect Dis       Date:  2003-06-23       Impact factor: 5.226

View more
  4 in total

1.  Novel genetic variation identified at fixed loci in ORF62 of the Oka varicella vaccine and in a case of vaccine-associated herpes zoster.

Authors:  Mark L Quinlivan; Nancy J Jensen; Kay W Radford; D Scott Schmid
Journal:  J Clin Microbiol       Date:  2012-02-29       Impact factor: 5.948

2.  Deep sequencing of viral genomes provides insight into the evolution and pathogenesis of varicella zoster virus and its vaccine in humans.

Authors:  Daniel P Depledge; Samit Kundu; Nancy J Jensen; Eleanor R Gray; Meleri Jones; Sharon Steinberg; Anne Gershon; Paul R Kinchington; D Scott Schmid; Francois Balloux; Richard A Nichols; Judith Breuer
Journal:  Mol Biol Evol       Date:  2013-10-25       Impact factor: 16.240

3.  Rates of vaccine evolution show strong effects of latency: implications for varicella zoster virus epidemiology.

Authors:  Lucy A Weinert; Daniel P Depledge; Samit Kundu; Anne A Gershon; Richard A Nichols; Francois Balloux; John J Welch; Judith Breuer
Journal:  Mol Biol Evol       Date:  2015-01-06       Impact factor: 8.800

4.  Deep Sequencing of Distinct Preparations of the Live Attenuated Varicella-Zoster Virus Vaccine Reveals a Conserved Core of Attenuating Single-Nucleotide Polymorphisms.

Authors:  Daniel P Depledge; Koichi Yamanishi; Yasuyuki Gomi; Anne A Gershon; Judith Breuer
Journal:  J Virol       Date:  2016-09-12       Impact factor: 6.549

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.